Traws Pharma (TRAW) Stock Price
Traws Pharma Price
Revenue has compounded at 4.6% per year over the past 14 years to 2.79 M USD. Traws Pharma's net margin stands at 328.7%, up from -7,151.8% several years earlier.
Traws Pharma stock price
Traws Pharma business model & stock analysis
Frequently asked questions about Traws Pharma
7 analysts currently rate the Traws Pharma stock: 0 recommend buying, 4 holding and 3 selling.
Converted at the current exchange rate, the Traws Pharma share trades at 0.40 EUR (0.44 USD).
The revenue cannot currently be calculated for Traws Pharma.
The expected profit of Traws Pharma is -10.63 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Traws Pharma is currently -0.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Traws Pharma stock.
The P/S cannot be calculated for Traws Pharma currently.
The Eulerpool Quality Score for Traws Pharma is 4/10.
The ISIN of Traws Pharma is US68232V8845. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Traws Pharma is TRAW. The ticker symbol is used to trade Traws Pharma shares on the stock exchange.
Traws Pharma stock
Traws Pharma Peer Group
All fundamentals and in-depth analysis of Traws Pharma
Our stock analysis for Traws Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Traws Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.